Commitment to Sustainability
Like many other manufacturing businesses, biopharmaceutical production imposes demands on natural resources and the environment, urging us all to think about the sustainability of future requirements for production and global supply.
In fact, one study states that the drug industry’s emission intensity in 2015 was 55% more than the auto industry1.
We’re pioneering sustainable biomanufacturing with the FastPharming System®. Our upstream raw materials include seeds, purified water/nutrients and photons. Compare that with traditional single-use mammalian cell culture systems that make extensive use of plastic consumables, energy-intensive water (water-for-injection [WFI]), filters, and upwards of 2,000 liter scale bioreactor operations requiring cell culture media consumables, energy to power the mixing, anti-foaming agents, and more.
We offer a more sustainable option for innovators looking to develop their process – an early decision that has a long-term impact. Making the choice today to use our plant-based expression system – delivering a greener, more sustainable process – is a decision that will have a lasting impact for decades as a product moves all the way from concept to commercial production.
1. Belkhir, L., et. al. (2018) “Carbon footprint of the global pharmaceutical industry and relative impact of its major players”. J Cleaner Production 214:185-194